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SUMMARY.-Human alpha fetoprotein (AFP) has been detected by the agar
double diffusion method in ascitic fluid, cerebrospinal fluid (CSF) and bile,
from fetuses, neonates and patients with AFP seropositive hepatocellular
carcinoma. AFP was detected in the meconium and faeces of fetuses and
neonates respectively. The protein was not detected in the amniotic fluid nor
the pericardial fluid. It was found in the urine in only two fetuses that had
concomittant renal disease. It was not detected in breast milk of lactating
females. When metastases occurred in the lung from a hepatocellular carci-
noma producing AFP, the pleural effusions sometimes contained AFP. The
concentrations of AFP in the serum and in the other body fluids were about
the same. This indicates that other body fluids can be used for the diagnosis
of hepatocellular carcinoma.
SINcE Pedersen (1944) described bovine fetuin, a fetal serum protein absent
in adult cattle serum, similar proteins have been observed in various mammals
including man (Abelev et al., 1963; Gitlin and Boesman 1967; Hull et al., 1969;
Tatarinov, 1964). The importance of alpha fetoprotein (AFP) in the diagnosis
of hepatocellular carcinoma was first demonstrated in mice (Abelev et al., 1963)
and then in man (Tatarinov, 1964). The relatively high incidence of primary
liver cell carcinoma in the tropics including Nigeria (Berman, 1951; Higginson,
1956; Edington and Maclean, 1965; British Medical Journal, 1970) provides
enough material forthe study ofthis protein. It was therefore decided to find out
whether AFP could be detected in other body fluids apart from serum.
In rural hospitals where facilities for serological diagnosis are inadequate, the
detection ofAFP in a body fluid such as urine will facilitate the diagnosis ofliver
cell carcinoma. Furthermore the distribution of AFP in the various body fluids
could be significant in elucidating its physiological role in normal and abnormal
conditions.
MATERIALS AND METHODS
Body fluids.-Blood bile, cerebrospinal fluid (CSF) and meconium were
obtained from 12 aborted fetuses, between 20 and 40 weeks gestation. Duodenal
juice, rectal faeces, pericardial fluid, blood, bile and CSF were obtained from
20 neonates whose ages ranged from 1 hour to 1 month. Six AFP positive liver
cell carcinoma patients and three AFP negative ones, aged between 24 years and
50 years, were also included. There were five pregnant women dying from various
diseases. These provided the amniotic fluid and breast milk as well as some of
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the fetal materials mentioned previously. Their periods of cyesis varied between
24 and 40 weeks. No patient with hepatoma in pregnancy was autopsied during
the time ofthis study. CSF, stool, ascitic fluid and urine from five living patients
diagnosed serologically and/or by needle biopsy as having hepatocellular carci-
nomawere also studied. ThreewereAFPpositiveandtwonegative. For controls
50 adult autopsied patients with various diseases were studied. Their ages
ranged from 6 weeks to over 60 years. Twelve live controls with meningitis,
congestive cardiac failure, malignant lymphoma, abdominal tuberculosis and
metastatic tumour to the liver were included.
Contamination of these fluids with blood was avoided during collection.
Specimens containing red blood cells microscopically were excluded from the
study. The CSF at autopsy was obtained from the brain by a ventricular tap in
fetuses and neonates. In adults, after removal the brain was placed on its side,
bisected and CSF was sucked offwith a Pasteur pipette from the lateral ventricle.
The specimen was centrifuged at 250 C. (room temperature) and 750 g for 5
minutes. The supernatant was kept in a sterile bijou bottle to which two drops of
1: 10,000 merthiolate were added as preservative, and then stored at 40 C.
Ascitic fluid, urine and liquor amnii were obtained by paracentesis. Bile was
obtained by needle aspiration of the exposed gall bladder. Breast milk was
obtained by manual expression into a sterile container. 0 5 ml. of phosphate
buffered saline (PBS), at pH 7 5, was added to 5 ml. of faeces, mixed and centri-
fuged and the supernatant was tested.
Anti8erum.-Rabbit antiserum to human alpha fetoprotein was obtained by
immunizing rabbits with 2 ml. mixture of 2 ml. pooled sera from AFP positive
liver cell carcinoma patients and 1 ml. complete Freund's adjuvant. The first
injection of the mixture was given subcutaneously and subsequent ones intra-
muscularly at weekly intervals up to three doses. The fifth dose was given intra-
muscularly, but as 1 ml. of serum only. The animals were bled 1 week later
according to the technique of Masopust et al., 1968). The antisera used for the
screening of the sera were kindly supplied by Doctors Abelev, Sizaret and Uriel.
The rabbit antiserum was made monospecific to human alpha fetoprotein (AFP)
by absorbing with an equal volume of pooled normal human sera from blood
donors and incubated for 30 minutes at 370 C. and 20 hours at 40 C. The precipi-
tate was removed by centrifugation in the cold (40 C.) at 500 g for 30 minutes and
the supernatant used (Abelev et al., 1967). The monospecificity was cross-checked
EXPLANATION OF PLATE
FIG. 1.
1 = AFP positive hepatoma serum
2 = Normal human serum A = AFP netative hepatoma serum
3 = Bile of (1) B = Fetus (28 weeks) serum
4 = Neonate (6 hours) serum C = Bile of (B)
5 = Bile of (4) D = Breast milk of mother of (B)
6 = Pleural effusion of (4) tE = Amniotic fluid of (B)
7 = Urine of (4)* F = Meconium of (B)
8 = Ascites of (4)
The central wells contain rabbit anti human AFP.
* This neonate had bilateral congenital hydronephrosis.
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with normal human serum, and AFP supplied by Dr. Sizaret. A line of identity
was produced with the three antisera sent by the three different laboratories,
although one was sheep antiserum to human AFP. Double diffusion was done
by the micro-Ouchterlony technique using 1% agar in barbitone buffer pH 8-6,
ionic strength 0-05 (Grant, 1964; Uriel, 1969, personal communication). The
central well with the rabbit antiserum and the peripheral wells with the test sera
were 0 5 cm. and 0-2 cm. in diameter respectively. The precipitin lines were
usually seen after about 5 hours in a moist chamber at room temperature, but the
results were read after 12 hours.
Concentration of AFP.-In order to estimate roughly the concentration of
AFP in the various fluids; serial double dilutions were made with PBS at pH 7.5
in small test tubes from 1: 2 to 1: 128 and 1: 5 to 1: 320. These were then put
in the peripheral wells with rabbit antiserum to AFP in the central well. The
precipitin lines were read after 12 hours.
RESULTS
A substance that is immunologically identical with serum AFP was detected
constantly in bile, CSF, faeces of neonates and meconium offetuses (Fig. 1). It
was however not detected in the urine except in two fetuses in which there was
associated congenital bilateral hydronephrosis. It was not detected in these
various fluids after about 1 month ofage but reappeared in some ofthem in adult
life particularly in patients with liver cell carcinomas that were secreting AFP
into the serum. The protein was present in the ascitic fluid of three fetuses,
eight neonates and all five AFP positive liver cell carcinoma patients. It was not
demonstrable inthe ascitic fluidofthree AFPnegativeliver cell carcinomapatients
two pregnant women and 20 controls. It was detected in meconium of fetuses
and faeces of neonates both in the duodenum and in the rectum. However, in
the AFP positive liver cell carcinoma patients it was detected only in the duodenal
contents. Of the five AFP positive liver cell carcinoma patients with non-
haemorrhagic pleural effusions, the protein was detected in the effusion in only
two.
It was absent in the pleural effusion of three neonates. There was no fetus
with effusion in this series. AFP was not detected in amniotic fluid and breast
milk (colostrum) of five pregnant patients and the pericardial fluid of all 113
patients (Table I). None ofthe liver cell carcinoma patients however had meta-
stases to the heart.
The concentration ofAFP was about the same in the serum as in all the various
body fluids in which the protein was detected. The range of concentration by
dilution was sto 1 in serum, bile, CSF, stool and ascitic fluid (Table II).
DISCUSSION
Detection of alpha fetoprotein in serum has been of value in the diagnosis of
hepatocellular carcinoma in man (Tatarinov, 1965; Kitheir et al., 1966; Foli et al.,
1969; Sherlock et al., 1970; Mawas et al., 1970; Sankale et al., 1970). Although
blood can be obtained from patients fairly easily, it was perhaps permissible to
look for the protein in other body fluids which can be obtained by medical auxil-
liaries in developing countries. The urine being the easiest was examined for
AFP. Since the molecular weight of human AFP is between 45,000 (Graham,
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Fetuses Neonates hepatoma hepatoma women Controls
Body fluids (12) (20) (9) (5) (5) (62)
1. Serum. + ± + _- -
2. Bile + + +
3. CSF + + . + - -
4. Urine .
5. Duodenal juice + + . +
6. Faeces in rectum + +
7. Pericardial fluid - -
8. Amniotic fluid . -(5) (0) . (0) (0) -(0)
9. Breast milk (Colostrum) (0) (0) (0) (0) - (0)
10. Ascites . +(3) +(8) +(5) -(3) -(2) -(20)
1 1. Pleural effusion . (0) -(3) ±(5) -(2) -(1) -(12)
Key: (a) + = present; (b) ±= sometimes present; (c) - absent; (d) the figures in brackets
represent the total number tested.
TABLE II.-Concentration of AFP in Various Body Fluids by Serial
Dilution




Body fluid (12) (20) (9)
(1) Serum . 40 32 32
(2) Bile . . 32 32 20
(3) CSF 20 20 20
(4) Duodenal juice . 20 20 20
(5) Ascites . 40 (3) 32 (8) 32 (5)
Key: (a) The figures in brackets represent the total number tested; (b) the value given in each
column is the average; (c) the range was 20-40.
(1966) cited by Van Furth and Adinolfi (1969)) and 70,000 (Gitlin and Boesman,
1967); it was thought that AFP might be found in the urine, just as is albumin
with a similar molecular weight (Zuhlke and Hermann, 1969). Of pertinence is
the fact that about 7500 of liver cell carcinoma in the tropics are associated with
cirrhosis (Edington and Gilles, 1969); and the so-called cirrhotic nephropathy
(Eisner and Levitt, 1961; Sakaguchi, 1968) might make small molecular weight
proteins pass the glomerular filter. It is tempting to suggest that failure to detect
AFP in the urine may be due to failure of filtration or failure to exceed the Tm
(tubular maximum reabsorption) value.
In an attempt to evolve a technique which is relatively easy and sensitive we
employed a latex agglutination technique, a modification of that of Morris et al.,
(1970). Latex particles were coated with the globulin fraction of rabbit anti-
human AFP globulin. The test was performed by mixing a drop ofthe sensitized
particles with a drop of serum from patients. Agglutination occurred only with
sera containing AFP. The detailed results will be published later.
There is very little known about the biological role of AFP in mammals
including man. However, the fact that AFP is a transient protein of fetal andFETOPROTEIN IN BODY FLUIDS 341
neonatal life suggests that it is probably related to the process ofdevelopment and
growth. The reappearance in adult life particularly in primary liver cell carci-
noma, like the carcinoembryonic antigen (CEA) in gastrointestinal epithelial
neoplasia (Gold, 1967), is indicative of dedifferentiation to the embryonal type
tissues, by these neoplasms. It has been reported that there seems to be no
correlation between the morphological appearance of human liver cell carcinoma
and the presence or absence of fetoprotein (Sankale et al., 1970; O'Conor et al.,
1970) but no biochemical lesion has been looked for. Factors which are respon-
sible for the appearance and disappearance of the protein are worthy of further
studies.
The finding of AFP in serum, bile, CSF and faeces, like most other serum
proteins, suggests that it plays a similar role in body homeostasis. Its exact role
and why it is switched offpostnatally but on again in hepatocellular carcinoma is
poorly understood.
Sherlock and her associates (1970) stated that AFP was detected in the ascitic
fluid of a patient with liver cell carcinoma. In the present series AFP was
detected in the ascitic fluids offive patients with primary liver cell carcinoma but
peritoneal metastases were not seen andmalignant cells were notfound on cytologi-
cal examination.
Since meconium is passed into the amniotic fluid it could be argued that AFP
should be detectable, but the dilutional factor is rather great. A more sensitive
technique or concentration ofthe fluid might improve the possibility of detection.
Gitlin and Boesman (1967) found that the fetal membranes do not secrete AFP
whilst Van Furth and Adinolfi (1969) stated that fetal placenta may secrete AFP.
Also Stanislawski-Birencwajg (1967) found AFP in rat amniotic fluid and cited
Lambotte et al. (1964) who found it in human amniotic fluid.
Because ofthe small molecular weight ofhuman AFP, it would be expected to
cross the placental barrier. Foy et al. (1970) reported 35% of pregnantwomen
having AFP in their sera. They were all over 30 weeks pregnant. Gitlin and
Boesman (1967) failed to find AFP in the maternal sera of 12 different mammalian
species with various types of placentation. They were all very near term in
gestation. Our findings tend to indicate that the situation in man is similar to
that described by the latter authors.
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